Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 8 , ISSUE 2 ( July-December, 2018 ) > List of Articles

CASE REPORT

Boceprevir-induced Herpes Zoster

Ayþegul Babalí, Basak Cakal, Alpaslan Tanoglu, Fatih Karaahmet, Murat Kekilli

Keywords : Boceprevir, Herpes zoster, Infection

Citation Information : Babalí A, Cakal B, Tanoglu A, Karaahmet F, Kekilli M. Boceprevir-induced Herpes Zoster. Euroasian J Hepatogastroenterol 2018; 8 (2):161-162.

DOI: 10.5005/jp-journals-10018-1282

License: CC BY-NC 4.0

Published Online: 01-01-2019

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Herpes zoster is caused by reactivation of the varicella zoster virus (VZV), that attacks peripheral or cranial nerves and result in painful cutaneous inflammation. Boceprevir is a protease inhibitor which used as a new therapeutic agent for chronic hepatitis C infection. Boceprevir associated herpes zoster is extremely rare condition. We present herpes zoster infection assosiated Boceprevir in patint with chronic hepatitis C.


PDF Share
  1. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014 Mar 10;7:125-132.
  2. Delemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014 Mar 10.
  3. Ridruejo E. Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2014 Mar;13(3):307-319.
  4. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013 Sep 3;81(10):928-930.
  5. Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013 Sep;125(5):78-91.
  6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics. 1981 Aug 1;30(2):239-245.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.